Anticancer Drug-induced Thyroid Dysfunction
Open Access
- 1 January 2020
- journal article
- review article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 16 (1) , 32-39
Abstract
The armamentarium of anticancer drugs available to an oncologist has grown rapidly over the past few decades. The use of cancer immunotherapy and targetedKeywords
Funding Information
- This article is published under the Creative Commons Attribution Non-commercial License.
This publication has 95 references indexed in Scilit:
- Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and TreatmentBioMed Research International, 2013
- Ten-year Experience of Bexarotene Therapy for Cutaneous T-cell Lymphoma in FinlandActa Dermato-Venereologica, 2012
- Thyroid Dysfunction from Antineoplastic AgentsJNCI: Journal of the National Cancer Institute, 2011
- Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastomaPediatric Blood & Cancer, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluationBritish Journal of Cancer, 2008
- Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromesAnnals of Hematology, 2008
- Interferon Alpha Treatment and Thyroid DysfunctionEndocrinology and Metabolism Clinics of North America, 2007
- Endocrine late effects from multi-modality treatment of neuroblastomaEuropean Journal of Cancer, 2005
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsNew England Journal of Medicine, 1988